0000899243-21-010270.txt : 20210308
0000899243-21-010270.hdr.sgml : 20210308
20210308082043
ACCESSION NUMBER: 0000899243-21-010270
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200831
FILED AS OF DATE: 20210308
DATE AS OF CHANGE: 20210308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cardama Alfonso Quintas
CENTRAL INDEX KEY: 0001760104
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38811
FILM NUMBER: 21720695
MAIL ADDRESS:
STREET 1: C/O TCR2 THERAPEUTICS INC.
STREET 2: 100 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC.
CENTRAL INDEX KEY: 0001750019
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 474152751
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-949-5200
MAIL ADDRESS:
STREET 1: 100 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-31
0
0001750019
TCR2 THERAPEUTICS INC.
TCRR
0001760104
Cardama Alfonso Quintas
TCR2 THERAPEUTICS INC.
100 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Medical Officer
Common Stock
2020-08-31
5
A
0
E
1118
10.098
A
3043
D
Common Stock
2021-02-28
5
A
0
E
708
16.1245
A
3751
D
The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2020 through August 31, 2020. This transaction is exempt under Rule 16b-3(c).
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020.
The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 1, 2020 through February 28, 2021. This transaction is exempt under Rule 16b-3(c).
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on September 1, 2020.
/s/ Margaret Siegel as Attorney-in-Fact
2021-03-08